Synthesis, Characterization, Antitumor Activity, and Theoretical Calculations of Co(Ⅱ) Complex Based on Pyridine-2, 6-dicarboxylic Acid

Li ZHANG Chang JIANG Lin-Feng GUO Xiao-Ling ZHANG Xiong-Qiang LIN Jie KANG Wei-Ming SUN

Citation:  Li ZHANG, Chang JIANG, Lin-Feng GUO, Xiao-Ling ZHANG, Xiong-Qiang LIN, Jie KANG, Wei-Ming SUN. Synthesis, Characterization, Antitumor Activity, and Theoretical Calculations of Co(Ⅱ) Complex Based on Pyridine-2, 6-dicarboxylic Acid[J]. Chinese Journal of Inorganic Chemistry, 2021, 37(2): 368-374. doi: 10.11862/CJIC.2021.027 shu


    通讯作者: 康杰,
  • 基金项目:

    福建省科技创新联合基金 2017Y9119

    福建省自然科学基金 2015J01597

    福建省高校杰出青年科研人才培育计划 2018B032

摘要: 以吡啶-2,6-二羧酸作为配体,在水热条件下合成了一种新的钴配合物:[Co(Hpdc)(bpy)Cl]·C2H5OH(H2pdc=吡啶-2,6-二羧酸,bpy=2,2'-联吡啶),并对其进行了红外和X射线单晶衍射表征。为了深入揭示该配合物的电子结构,采用密度泛函理论来研究其电荷分布、静电势、前沿分子轨道以及在溶液条件下的相关电子性能。我们采用溴化噻唑蓝四氮唑(MTT)法测试了该配合物对慢性粒细胞白血病(K562)和食管癌(OE-19)细胞的抗肿瘤活性,其IC50值仅为(0.22±0.05)μg·mL-1和(0.82±0.16)μg·mL-1(即(0.48±0.11)μmol·L-1和(1.77±0.35)μmol·L-1),表明该化合物对这2种癌细胞系具有较强的细胞毒性。


  • Nowadays, cancers have become the most serious threat to human′s health worldwide[1]. It is reported that annual cancer cases will rise to 26 million within the next twenty years[2]. Unfortunately, there is no effective therapy for curing most of tumors up to now, and thus, it is still greatly desired to explore novel chemotherapeutic agents for oncotherapy[3-4]. Consequently, plentiful efforts have been devoted to exploring new antitumor drugs during the past decades. Among them, metallotherapeutics have attracted great attention since the discovery of cisplatin more than five decades ago[5-7]. Such metal-base drugs can prevent cancer cell division and then result in cancer cell apoptosis by inducing DNA damage and disrupting DNA repair process[8-9].

    It is known that cisplatin is one of the most commonly used drugs in clinical treatment of numerous forms of human cancers, such as testicular and ovarian cancers, neck and head tumors[10-12]. Despite the great utility of cisplatin, its therapeutic value is also accompanied by serious side effects[13] and the increasing drug resistance[14]. This has created a continuous momentum in developing platinum - based drugs[15-16], and thus a few drugs, such as carboplatin, oxaliplatin, nedaplatin, lobaplatin, and heptaplatin have been successfully employed for clinical use in the past several decades. Such great successful clinical applications of platinum-based complexes as well as the accompanying toxicity and resistance have stimulated more research interests to search for other alternative transition metal (TM) coordination complexes in the area of metallotherapeutics.

    In recent years, a great amount of Co-based compounds with antitumor activities have been achieved by employing different kinds of ligands[17-21]. To explore novel Co-based antitumor compounds, an interesting multidentate ligand, pyridine-2, 6-dicarboxylic acid (H2pdc) attracted our great interest because that it has a rigid 120° angle between the central pyridine ring and two carboxylate groups, and therefore could potentially provide various coordination modes to form both discrete and consecutive metal complexes[22]. Up to now, a large number of coordination compounds with intriguing topological structures have been constructed by using this ligand[23-29]. Motivated by the above information, a novel Co(Ⅱ)-based coordination compound [Co (Hpdc)(bpy)Cl]·C2H5OH (bpy=2, 2′-bipyridine) has been synthesized in this work. This complex was characterized by experimental analyses and theoretical computations. Theoretical results indicate that this complex is a good candidate for antitumor agents, and therefore, its inhibition against chronic myelocytic leukemia (K562) and esophageal carcinoma (OE-19) cells was determined by using thiazolyl blue tetrazolium bromide (MTT) assay. Our results reveal that this complex possesses certain antiproliferation effects on both of K562 and OE-19 cells with low IC50 values of (0.22±0.05) μg·mL-1 and (0.82±0.16) μg·mL-1, respectively.

    All chemicals were purchased commercially and used without further purification. The K562 and OE-19 cells were obtained from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Elemental analyses (C, H, N) were carried out with a Perkin-Elmer 240 elemental analyzer. Infrared spectrum was recorded in a range of 400~4 000 cm-1 on a Perkin-Elmer Spectrum-2000 FT-IR spectrometer using KBr pellets.

    A mixture of H2pdc (2.05 mmol, 0.342 g) and 2, 2′bipyridine (1.20 mmol, 0.294 g) was dissolved in deionized water (10 mL). After stirring for 15 minutes, 1.20 mmol CoCl2·6H2O (0.286 g) was added into the above solution along with adding 5 mL absolute ethyl alcohol. Then, the mixture was continuously stirred at room temperature for 3 h, resulting in pellucid light green solution. After being filtrated and the filtration standing at room temperature for one week, reddish brown columnar crystals of [Co(Hpdc) (bpy)Cl]·C2H5OH were obtained (Yield: 55% based on Co). Anal. Calcd. for C19H18ClCoN3O5(%): C, 49.32; H, 3.92; N, 9.08. Found (%): C, 49.23; H, 3.99; N, 9.16. IR (KBr pellet, cm-1): 3 590~2 815 (br), 2 360 (w), 1 619 (vs), 1 430 (m), 993 (w), 734 (w).

    X-ray data of Co(Hpdc)(bpy)Cl·C2H5OH was collected on a Rigaku Saturn 724 CCD diffractometer equipped with a graphite-monochromator Mo radiation (λ=0.071 073 nm) using an ω scan mode at 293(2) K. Absorption corrections were applied using multiscan methods. Data reduction was performed using the Rigaku Americas Corporation′s Crystalclear program[30]. This structure was solved by direct methods and refined by full-matrix least-squares using the SHELXS-97[31] and SHELXL-2018/1[32], respectively. All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were located geometrically and treated as riding atoms with a common fixed isotropic thermal parameter.

    CCDC: 1994088.

    The geometric structure of [Co(Hpdc)(bpy)Cl] with all real frequencies was optimized by using the PBE0 method in conjunction with the LANL2DZ basis set for Co atom and 6-31+G(d, p) basis set for the other atoms. The doublet structure with the lowest spin state is found to be the most stable molecular configuration of [Co(Hpdc) (bpy)Cl] by considering different spin states in structural optimization. The electrostatic potential (ESP), nature population analysis (NPA) charges, frontier molecular orbitals (FMO), and various electronic properties of [Co(Hpdc) (bpy)Cl] were obtained at the PBE0/6 -31++G(d, p) & LANL2DZ level based on the optimized configuration. Herein, chemical hardness (η), global electronegativity (χ), electrophilicity index (ω), chemical potential (CP) and softness (S) are defined as follows[33-35]:

    $ {\chi = \frac{{\mid {\rm{VIE}} + {\rm{VEA}}\mid }}{2}} $


    $ {{\rm{CP}} = \frac{{|{\rm{VIE}} + {\rm{VEA}}|}}{2}} $


    $ {\eta = \frac{{{\rm{VIE}} - {\rm{VEA}}}}{2}} $


    $ {\omega = \frac{{{{({\rm{CP}})}^2}}}{{2\eta }}} $


    $ {S = \frac{1}{{2\eta }}} $


    To minimize the inaccuracy of the aforementioned parameters due to the self-interaction error (SIE) of density functional theory (DFT) methods[36-37], the vertical electronic affinity (VEA) and vertical ionization energy (VIE) were not directly approximated from the HOMO-LUMO energy (i. e., Koopman′s theorem). Instead, they are calculated by using the following equations[38]:

    $ {\rm{VIE = }}{E_{{\rm{cation}}}}{\rm{ - }}{E_{{\rm{neutral}}}} $


    $ {\rm{VIE = }}{E_{{\rm{neutral}}}}{\rm{ - }}{E_{{\rm{anion}}}} $


    where Eneutral represents the electronic energy of the optimized neutral structure, while Ecation and Eanion are the cationic and anionic energies calculated at optimized neutral geometry, respectively.

    All the above calculations were carried out by using the Gaussian 16 program package[39], in which the self-consistent reaction field (SCRF) calculations with the polarizable continuum model (PCM) [40] were performed to consider the solvent effect of water. Dimensional plots of molecular configurations and orbitals were generated with the GaussView program[41]. The electrostatic potential (ESP) was obtained by employing Multiwfn program package[42] in conjunction with the VMD software[43].

    Cytotoxicity of this complex was assessed by MTT assay. Briefly, the K562 and OE-19 cells were cultivated into suspension cells in the 0.25% pancreatic protein. Then, the suspension liquid with 1×105 cells per milliliter was seeded into a 96-well culture plate with 100 μL per well. After incubation at 37 ℃ in a 5% (V/V) CO2 incubator for 24 h, the samples containing the synthesized complex of serial concentrations were added into the wells of the experimental groups (10 μL per well). DMSO without this complex was added into the well of the control group (10 μL per well). The cells were sequentially incubated for 72 h, followed by the addition of 20 μL MTT solution (5 mg·mL-1) to each well and further cultivation for 4 h. Afterwards, the supernatant with MTT was removed and followed by the addition of 150 μL DMSO to dissolve formazan dye for 10 min at room temperature along with slow oscillation. Finally, the optical density (OD) at 490 nm was read by an enzyme-linked immunosorbent assay (ELISA) reader and the inhibition rate (IR=(1-ODcomplex/ODblank)×100%) were calculated. The median inhibitory concentration (IC50) values were obtained from the results of quadruplicate determinations of at least three independent experiments. Herein, the samples containing the titled complex were obtained by dissolving the isolated crystals into the DMSO following the high temperature sterilization. Thereafter, these solutions were diluted by RPMI 1640 nutrient solution to the concentrations of 100, 50, 25, 12.5, 6.25, 3.13, 1.56, and 0.78 μg·mL-1.

    The synthesized complex [Co(Hpdc) (bpy)Cl]·C2H5OH appears as a reddish brown columnar crystal. Herein, the crystal structure of this complex is shown in Fig. 1 in conjunction with the theoretically optimized molecular structure of [Co(Hpdc)(bpy)Cl], while the 3D network is given in Fig. S1 (Supporting information). Crystallographic data are collected in Table 1, and selected bond lengths and angles from experimental and theoretical characterization are listed in Table S1.

    Figure 1

    Figure 1.  Molecular structures of (a) [Co(Hpdc)(bpy)Cl]·C2H5OH obtained by experiment and (b) [Co(Hpdc)(bpy)Cl] in water from theoretical calculation with atom numbering

    Table 1

    Table 1.  Crystallographic data collection and structure refinement details of [Co(Hpdc)(bpy)Cl]·C2H5OH
    下载: 导出CSV
    Empirical formula C19H18ClCoN3O5
    Formula weight 462.74
    Crystal system Monoclinic
    Space group P21/n
    a / nm 1.089 8(2)
    b / nm 1.712 5(3)
    c / nm 1.141 2(2)
    β / (°) 105.29(3)
    V / nm3 2.054 3(8)
    Z 4
    μ/ mm-1 1.001
    Dc / (g·cm-3) 1.496
    θ range / (°) 3.01~27.48
    Index ranges -14 ≤ h ≤ 14, -22 ≤ k ≤ 22, -13 ≤ l ≤ 14
    Reflection collected 19 862
    Unique reflection 4 696
    Observed reflection [I>2σ(I)] 4 095
    F(000) 948
    Rint 0.024 7
    Goodness of fit on F2 0.986
    R1 [I > 2σ(I)]a 0.031 0
    wR2 [I>2σ(I)]b 0.081 7
    R1 (all data) 0.037 1
    wR2 (all data) 0.085 5
    ρ)max, (Δρ)min / (e·nm-3) 579, -315
    a R1=∑||Fo|-|Fc||/∑|Fo|; b wR2={∑[w(Fo2-Fc2)2]/∑[w(Fo2)2]}1/2

    As shown in Table 1, the crystal structure of [Co(Hpdc) (bpy)Cl]·C2H5OH belongs to P21/n space group of monoclinic system. As shown in Fig. 1a, its molecular structure in the crystal is composed of one Co2+, one 2, 6-Hpdc- anion, one 2, 2′-bipyridine, one Cl-, and one guest alcohol molecule. It is observed that the Co2+ ion in this complex is six-coordinated: two carboxylate oxygen atoms and one nitrogen atom from the pdc2- ligand, two nitrogen atoms from 2, 2′bipyridine, and one Cl- anion. As shown in Table S1, the bond lengths of Co—N1, Co—N2, Co—N3, Co— O1, Co—O3, and Co—Cl are 0.208 43(13), 0.212 80(14), 0.209 60(16), 0.218 12(13), 0.232 20(14), and 0.234 26(10) nm, respectively, which are consistent with those of previously reported Co-based complexes[44-45]. These subunits of [Co(Hpdc)(bpy)Cl]·C2H5OH are linked together by hydrogen bonds to form a stable 3D framework (Fig.S1), and the values of hydrogen bond lengths and angles for [Co(Hpdc) (bpy)Cl] ·C2H5OH are listed in Table S2.

    It is known that the practical application of such complex usually needs to dissolve it into water. Thus, it is meaningful to further reveal the electronic structure and relevant properties of this novel complex dissolved in water. So, the isolated [Co(Hpdc)(bpy)Cl] motif from experimental crystal structure has been re-optimized at the PBE0/6-31+G(d, p) & LANL2DZ level by considering the water solvent. Herein, the ethanol molecule in this complex has been neglected because that ethanol is easily dissolved in water and then has little effect on the structure and properties of [Co(Hpdc) (bpy)Cl] in aqueous solution. After optimization, it is found that the calculated Co—N1 (0.195 6 nm), Co—N2 (0.198 0 nm), Co—N3 (0.200 0 nm), Co—O1 (0.215 9 nm), and Co—Cl (0.233 8 nm) bond lengths are slightly shorter than those obtained by the single crystal XRD experiment, while the bond length of Co—O3 (0.245 5 nm) is longer than that from the experiment. And the differences between the theoretical and the experimental values of ∠N—Co—N and ∠O—Co—O angles are smaller than 9°. Hence, the optimized Co(Hpdc) (bpy)Cl in aqueous solution exhibits a very similar geometric structure to that obtained from crystal characterization, indicating that the used theoretical method in this work is reliable. The slight inconsistencies in the bond lengths and angles are commonly found in previously reported literatures[44, 46-48], which can be attributed to the fact that the environment of crystal lattice in the experiment is different from the aqueous condition used in theoretical simulation.

    Firstly, the experimental IR spectrum of this studied complex has been shown in Fig. S2. Herein, the strong vibrations appearing around 1 620 and 1 400 cm-1 correspond to the asymmetric and symmetric stretching vibrations of the carboxylate group, respectively. The absorption bands in a range of 650~670 cm-1 and 720~750 cm-1 in the fingerprint region are attributed to Co—O and Co—N vibrations, respectively.

    In view of the fact that the synthesized complex will become a monomer after being dissolved into water, the molecular model from theoretical optimization will be closer to its real state after entering cells. Therefore, a detailed study on the electronic structure of this complex was performed on the basis of the theoretically optimized [Co(Hpdc) (bpy)Cl]. The charge distribution, ESP, FMO, and various global reactivity parameters of [Co(Hpdc) (bpy)Cl] in aqueous solution will be discussed in the following sections.

    To clearly reveal the distribution of charges in this complex, the calculated NPA charges of [Co(Hpdc) (bpy)Cl] are displayed in Fig.S3. It can be seen that the negative charges mainly distribute on the electronegative O, N, and Cl atoms in [Co(Hpdc)(bpy)Cl], while Co carries a positive charge of 0.580. In addition, the ESP picture of [Co(Hpdc) (bpy)Cl] is given in Fig. 2. As shown in Fig. 2, the positive electrostatic potential mainly locates on peripheral hydrogen atoms of Hpdc- and bpy ligands. It is found that the hydrogen of carboxyl in [Co(Hpdc)(bpy)Cl] has the largest positive potential of 317.02 kJ·mol-1, indicating that this hydrogen atom has a large tendency to form hydrogen bond with N or O atoms of DNA bases when it approaches DNA in cells. In another respect, the Cl atoms in [Co(Hpdc) (bpy)Cl] are surrounded by large negative potential, which is consistent with the NBO analysis. Also, the HOMO and LUMO orbitals of [Co(Hpdc)(bpy) Cl] are depicted in Fig. 3. It is observed that this complex has large HOMO-LUMO gaps of 4.30 and 4.40 eV for α and β electrons, indicating that it also has high chemical stability.

    Figure 2

    Figure 2.  ESP diagram of [Co(Hpdc)(bpy)Cl] in water phase at PBE0/6-31++G(d, p)&LANL2DZ level

    Figure 3

    Figure 3.  Frontier molecular orbitals of [Co(Hpdc)(bpy)Cl] in water phase at PBE0/6-31++G(d, p)&LANL2DZ level

    To further reveal the electronic properties of this complex, the global reactivity parameters, including VEA, VIE, η, χ, ω, CP, and S of [Co(Hpdc) (bpy)Cl] were also calculated and summarized in Table S3. These theoretical results may provide some references for experimentalists in the future. In addition, it is known that the molecular dipole moment has an obvious effect on the intermolecular interaction between drug molecules and drug targets[47]. As shown in Table S3, the dipole moment of [Co(Hpdc)(bpy)Cl] was found to be 7.17 a.u., indicating that this complex is soluble in polar solvent, such as water. Moreover, it is reported that the increase in polarizability of aromatic ring complexes can enhance the interaction between them and the DNA of tumor cells[24]. From Table S3, it is found that, with two ligands containing aromatic rings, the polarizability of [Co(Hpdc)(bpy)Cl] is as large as 376 a.u., suggesting that this complex is also likely to interact with DNA. These static electric properties again imply that this complex is a good candidate to serve as a new antitumor metallotherapeutic agent. Consequently, it is of great interest to evaluate the antitumor activity of this complex in experiment.

    The growth inhibitory effect of [Co(Hpdc)(bpy)Cl]· C2H5OH on two kinds of human tumor cells, i.e., K562 and OE-19 cells in vitro were evaluated by MTT assay. The inhibition rates on K562 and OE-19 under different concentrations of this complex are listed in Table S4 and plotted in Fig. 4. As shown in Fig. 4, it is observed that the inhibition rates on K562 and OE-19 gradually increased along with the increasing concentrations of this complex. In particular, the estimated IC50 values of this complex for K562 and OE-19 cells were (0.22±0.05) μg·mL-1 and (0.82±0.16) μg·mL-1 (i.e., (0.48±0.11) μmol·L-1 and (1.77±0.35) μmol·L-1), respectively. These small IC50 values demonstrate that this complex is quite effective in restraining the growth of K562 and OE-19 cells. Besides, it is noted that the IC50 value for K562 was much smaller than that for OE19, indicating that this complex is more cytotoxic for K562 cells. More interestingly, the IC50 value ((0.22± 0.05) μg·mL-1) of [Co(Hpdc) (bpy)Cl] ·C2H5OH on K562 cell was less than those of 0.70~1.86 μg·mL-1 previously reported for cisplatin[49-52], which further verifies the inhibitory effect of this Co-based compound on K562 cells.

    Figure 4

    Figure 4.  Inhibition rates of [Co(Hpdc)(bpy)Cl]·C2H5OH against the K562 and OE-19 tumor cells under different concentrations

    In summary, a Co(Ⅱ)-based coordination compound [Co(Hpdc) (bpy)Cl] ·C2H5OH has been synthesized and characterized by IR spectrum, elemental analysis, and single-crystal X-ray diffraction. Also, the electronic structure of this complex in water was also detailedly studied by using DFT calculations. Moreover, its antitumor activity was experimentally studied by MTT assay in K562 and OE-19 cancer cell lines. The experimental results show that this novel complex indeed exhibits a significant antitumor activity against K562 and OE-19 cells, which demonstrates its great potential of serving as a new antitumor agent. This work will not only provide a novel Co-based complex as potential antitumor agent, but also intrigue more interest in exploring the synthesis and application of new coordination complexes in biomedical field.

    Supporting information is available at

    1. [1]

      Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D M, Forman D, Bray F. Int. J. Cancer, 2015, 136(5):E359-E386 doi: 10.1002/ijc.29210

    2. [2]

      Thun M J, DeLancey J O, Center M M, Jemal A, Ward E M. Carcinogenesis, 2009, 31(1):100-110

    3. [3]

      Tomasetti C, Li L, Vogelstein B. Science, 2017, 355(6331):1330-1334 doi: 10.1126/science.aaf9011

    4. [4]

      Livingston D M, Silver D P. Nature, 2008, 451(7182):1066-1067 doi: 10.1038/4511066a

    5. [5]

      Rosenberg B, Vancamp L, Krigas T. Nature, 1965, 205(4972):698-699 doi: 10.1038/205698a0

    6. [6]

      Rosenberg B, Vancamp L, Trosko J E, Mansour V H. Nature, 1969, 222(5191):385-386 doi: 10.1038/222385a0

    7. [7]

      Hurley, Laurence H. Nat. Rev. Cancer, 2002, 2(3):188-200 doi: 10.1038/nrc749

    8. [8]

      Hartinger C G, Dyson P J. Chem. Soc. Rev., 2009, 38(2):391-401 doi: 10.1039/B707077M

    9. [9]

      Thota S, Rodrigues D A, Crans D C, Barreiro E J. J. Med. Chem., 2018, 61(14):5805-5821 doi: 10.1021/acs.jmedchem.7b01689

    10. [10]

      Bakalova A, Varbanov H, Buyukliev R, Momekov G, Ferdinandov D, Konstantinov S, Ivanov D. Eur. J. Med. Chem., 2008, 43(5):958-965 doi: 10.1016/j.ejmech.2007.06.025

    11. [11]

      Galanski M, Arion V B, Jakupec M A, Keppler B K. Curr. Pharm. Des., 2003, 9(25):2078-2089 doi: 10.2174/1381612033454180

    12. [12]

      Tanaka T, Yukawa K, Umesaki N. Oncol. Rep., 2005, 14(5):1365-1369

    13. [13]

      Rabik C A, Dolan M E. Cancer Treat. Rev., 2007, 33(1):9-23 doi: 10.1016/j.ctrv.2006.09.006

    14. [14]

      Ohmichi M, Hayakawa J, Tasaka K, Kurachi H, Murata Y. Trends Pharmacol. Sci., 2005, 26(3):113-116 doi: 10.1016/

    15. [15]

      Galanski M. Recent Patents Anti-Canc. Drug Discov., 2006, 1(2):285-295 doi: 10.2174/157489206777442287

    16. [16]

      Shaili E. Sci. Prog., 2014, 97(1):20-40 doi: 10.3184/003685014X13904811808460

    17. [17]

      陈战芬, 马艺丹, 华罗光, 张健.无机化学学报, 2014, 30(7):1525-1534 Z F, MA Y D, HUA L G, ZHANG J. Chinese J. Inorg. Chem., 2014, 30(7):1525-1534

    18. [18]

      Pires B M, Giacomin L C, Castro F A V, Amanda D S C, Pereira M D, Bortoluzzi A J, Faria R B, Scarpellini M. J. Inorg. Biochem., 2016, 157:104-113 doi: 10.1016/j.jinorgbio.2016.01.024

    19. [19]

      解庆范, 郭妙莉, 陈延民.无机化学学报, 2018, 34(2):309-316 Q F, GUO M L, CHEN Y M. Chinese J. Inorg. Chem., 2018, 34(2):309-316

    20. [20]

      Li J, Zhang J, Zhang Q, Wang Y, Bai Z, Zhao Q, He D, Wang Z, Zhang J, Chen Y. Bioorg. Med. Chem., 2019, 27(20):115071 doi: 10.1016/j.bmc.2019.115071

    21. [21]

      Khan H Y, Ansari M O, Shadab G G H A, Tabassum S, Arjmand F. Bioorg. Chem., 2019, 88(2019):102963

    22. [22]

      Chuasaard T, Panyarat K, Rodlamul P, Chainok K, Yimklan S, Rujiwatra A. Cryst. Growth Des., 2017, 17(3):1045-1054 doi: 10.1021/acs.cgd.6b01389

    23. [23]

      Xu J, Su W, Hong M. Cryst. Growth Des., 2011, 11(1):337-346 doi: 10.1021/cg101343k

    24. [24]

      Ghosh S K, Ribas J, Bharadwaj P K. CrystEngComm, 2004, 6(45):250-256 doi: 10.1039/B407571D

    25. [25]

      Bordbar M, Tabatabaee M, Alizadeh-Nouqi M, Mehri-Lighvan Z, Khavasi H R, YeganehFaal A, Fallahian F, Dolati M. J. Iran. Chem. Soc., 2016, 13(6):1125-1132 doi: 10.1007/s13738-016-0826-x

    26. [26]

      Ghosh S K, Bharadwaj P K. Inorg. Chem., 2004, 43(7):2293-2298 doi: 10.1021/ic034982v

    27. [27]

      Ghosh S K, Bharadwaj P K. Inorg. Chem., 2005, 44(9):3156-3161 doi: 10.1021/ic048159q

    28. [28]

      Derikvand Z, Dorosti N, Hassanzadeh F, Shokrollahi A, Mohammadpour Z, Azadbakht A. Polyhedron, 2012, 43(1):140-152 doi: 10.1016/j.poly.2012.06.026

    29. [29]

      Deng D, Liu P, Fu W, Li L, Yang F, Ji B. Inorg. Chim. Acta, 2010, 363(5):891-898 doi: 10.1016/j.ica.2009.12.044

    30. [30]

      CrystalClear 1.40, Rigaku Americas Corp, The Woodlands, TX, 2008.

    31. [31]

      Sheldrick G M. SHELXL-97, Program for the Solution of Crystal Structures, University of Göttingen, Germany, 1997.

    32. [32]

      Sheldrick G M. SHELXL-2018/1, Program for the Refinement of Crystal Structures, University of Göttingen, Germany, 2018.

    33. [33]

      Hutama A S, Huang H, Kurniawan Y S. Spectrochim. Acta. A Mol. Biomol. Spectrosc., 2019, 221:117152

    34. [34]

      Parr R G, Donnelly R A, Levy M, Palke W E. J. Chem. Phys., 1978, 68(8):3801-3807 doi: 10.1063/1.436185

    35. [35]

      Parr R G, Szentpaly L V, Liu S. J. Am. Chem. Soc., 1999, 121(9):1922-1924

    36. [36]

      Cohen A J, Mori-Sánchez P, Yang W. Science, 2008, 321(5890):792-794 doi: 10.1007%2F128_2011_195

    37. [37]

      Mori-Sanchez P, Cohen A J, Yang W. J. Chem. Phys., 2006, 125(20):2604-308

    38. [38]

      Lu C, Kuang X Y, Lu Z W, Mao A J, Ma Y M. J. Phys. Chem. A, 2011, 115(33):9273-9281

    39. [39]

      Frisch M J, Trucks G W, Schlegel H B, Scuseria G E, Robb M A, Cheeseman J R, Scalmani G, Barone V, Petersson G A, Nakatsuji H, Li X, Caricato M, Marenich A V, Bloino J, Janesko B G, Gomperts R, Mennucci B, Hratchian H P, Ortiz J V, Izmaylov A F, Sonnenberg J L, Williams-Young D, Ding F, Lipparini F, Egidi F, Goings J, Peng B, Petrone A, Henderson T, Ranasinghe D, Zakrzewski V G, Rega N, Gao J, Zheng G, Liang W, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Throssell K, Montgomery JrJA, Peralta J E, Ogliaro F, Bearpark M J, Heyd J J, Brothers E N, Kudin K N, Staroverov V N, Keith T A, Kobayashi R, Normand J, Raghavachari K, Rendell A P, Burant J C, Iyengar S S, Tomasi J, Cossi M, Millam J M, Klene M, Adamo C, Cammi R, Ochterski J W, Martin R L, Morokuma K, Farkas O, Foresman J B, Fox D J. Gaussian 16, Revision A.03, Gaussian, Inc., Wallingford, 2016.

    40. [40]

      Scalmani G, Frisch M J. J. Chem. Phys., 2010, 132(11):114110

    41. [41]

      Dennington R, Keith T, Millam J. GaussView, Ver. 6, KS, USA: Semichem Inc, Shawnee Mission, 2016.

    42. [42]

      Lu T, Chen F J. Comput. Chem., 2012, 33(5):580-592

    43. [43]

      Humphrey W, Dalke A, Schulten K. J. Mol. Graphics, 1996, 14(1):33-38

    44. [44]

      Stamatatos T C, Pringouri K V, Raptopoulou C P, Vicente R, Psycharis V, Escuer A, Perlepes S P. Inorg. Chem. Commun., 2006, 9(12):1178-1182

    45. [45]

      Marques L F, Marinho M V, Speziali N L, Visentin L D C, Machado F C. Inorg. Chim. Acta, 2011, 365(1):454-457

    46. [46]

      Ghasemi K, Rezvani A R, Shokrollahi A, Moghimi A, Gavahi S, García-Granda S, Mendoza-Meroño R. C. R. Chim., 2014, 17(12):1221-1229

    47. [47]

      Gao H. Spectrochim. Acta Part A Mol. Biomol. Spectrosc., 2011, 79(3):687-693

    48. [48]

      Štarha P, Marek J, Trávníček Z. Polyhedron, 2012, 33(1):404-409

    49. [49]

      Krstic N M, Matic I Z, Juranic Z D, Novakovic I T, Sladic D M. J. Steroid. Biochem. Mol. Biol., 2014, 143:365-375

    50. [50]

      Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M. Cancer Res., 1989, 49(15):4098-4102

    51. [51]

      Han Q B, Li R T, Zhang J X, Sun H D. Helv. Chim. Acta, 2004, 87(5):1119-1124 doi: 10.1002/chin.200444202

    52. [52]

      Su W C, Chang S L, Chen T Y, Chen J S, Tsao C J. Jpn. J. Clin. Oncol., 2000, 30(12):562-567

  • Figure 1  Molecular structures of (a) [Co(Hpdc)(bpy)Cl]·C2H5OH obtained by experiment and (b) [Co(Hpdc)(bpy)Cl] in water from theoretical calculation with atom numbering

    Figure 2  ESP diagram of [Co(Hpdc)(bpy)Cl] in water phase at PBE0/6-31++G(d, p)&LANL2DZ level

    Figure 3  Frontier molecular orbitals of [Co(Hpdc)(bpy)Cl] in water phase at PBE0/6-31++G(d, p)&LANL2DZ level

    Figure 4  Inhibition rates of [Co(Hpdc)(bpy)Cl]·C2H5OH against the K562 and OE-19 tumor cells under different concentrations

    Table 1.  Crystallographic data collection and structure refinement details of [Co(Hpdc)(bpy)Cl]·C2H5OH

    Empirical formula C19H18ClCoN3O5
    Formula weight 462.74
    Crystal system Monoclinic
    Space group P21/n
    a / nm 1.089 8(2)
    b / nm 1.712 5(3)
    c / nm 1.141 2(2)
    β / (°) 105.29(3)
    V / nm3 2.054 3(8)
    Z 4
    μ/ mm-1 1.001
    Dc / (g·cm-3) 1.496
    θ range / (°) 3.01~27.48
    Index ranges -14 ≤ h ≤ 14, -22 ≤ k ≤ 22, -13 ≤ l ≤ 14
    Reflection collected 19 862
    Unique reflection 4 696
    Observed reflection [I>2σ(I)] 4 095
    F(000) 948
    Rint 0.024 7
    Goodness of fit on F2 0.986
    R1 [I > 2σ(I)]a 0.031 0
    wR2 [I>2σ(I)]b 0.081 7
    R1 (all data) 0.037 1
    wR2 (all data) 0.085 5
    ρ)max, (Δρ)min / (e·nm-3) 579, -315
    a R1=∑||Fo|-|Fc||/∑|Fo|; b wR2={∑[w(Fo2-Fc2)2]/∑[w(Fo2)2]}1/2
    下载: 导出CSV
  • 加载中
  • PDF下载量:  0
  • 文章访问数:  5
  • HTML全文浏览量:  1
  • 发布日期:  2021-02-10
  • 收稿日期:  2020-07-07
  • 修回日期:  2020-10-28
通讯作者: 陈斌,
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索